InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $1.315 0.2 (17.94%)+
Announcement
Release
7 Nov 2025 8:26AM
Price at Release
$1.115
Full Release
download
Summary
AVITA Medical, Inc. reported its third-quarter financial results for 2025, highlighting a 13% decrease in commercial revenue to $17.1 million due to Medicare Administrative Contractors' reimbursement challenges. Despite this, the company achieved a significant 24% reduction in operating expenses to $23.0 million. Notably, the CE Mark approval for RECELL GO® in Europe has bolstered its market presence, expanding into Germany, Italy, and the UK. The data presentation at the Southern Region Burn Conference underscored RECELL's efficacy in wound treatment. AVITA's focus remains on optimizing its U.S. market strategy, concentrating on 200 key burn and trauma centers, and improving cash management, having reduced its net cash usage to $6.2 million. The company anticipates full-year 2025 revenue between $70 to $74 million, revising down the earlier estimate of $76 to $81 million.
Key Points
  • Commercial revenue decreased by 13% to $17.1 million.
  • CE Mark approval for RECELL GO® facilitates European expansion.
  • Operating expenses were reduced by 24% to $23.0 million.
  • Net loss improved to $13.2 million from $16.2 million in Q3 2024.
  • Focus on U.S. market strategy with 200 key burn and trauma centers.
  • Reimbursement clarity restored under new Category I CPT codes.
  • Projected full-year 2025 revenue between $70 and $74 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.